Tag: Trial
Summary Sunitinib is associated with a robust objective response rate in patients with metastatic clear cell renal cell carcinoma
(RCC). The primary objective of this phase II clinical trial was to assess the overall response rate for sunitinib in patients
with papillary metastatic RCC as well as other non-clear cell histologies. A Simon 2-stage design was used to determine the
number of papillary metastatic RCC patients for enrollment, and allowed for descriptive response data for other non-clear
cell histologies. Twenty-three patients were enrolled, including 8 with papillary renal cell carcinoma (RCC) and the remainder
with other non-clear cell histologies (unclassified in 5 patients). All patients received 50 mg of oral sunitinib in cycles
of 4 weeks followed…
Source: MedWorm: Oral Cancer
Tags: carcinoma, cell, Metastatic, nonclear, patients, Phase, renal, Sunitinib, Trial
Posted in Treatment | No Comments »
SHEFFIELD, England, Aug. 13 (UPI) — A British team of researchers say they has been awarded a $2 million grant to perfect a test dentists can use to detect oral cancer through mouth cells.
Cancer – Health – Conditions and Diseases – England – Head and Neck (Source: Health News – UPI.com)
Source: MedWorm: Oral Cancer
Tags: Cancer, Oral, test, Trial, under
Posted in Treatment | No Comments »
Conclusion
These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation. (Source: Journal of Clinical Oncology)
Source: MedWorm: Oral Cancer
Tags: analysis, Anastrozole, ATAC, body, Breast, Cancer, effect, exploratory, index, mass, Recurrences, Tamoxifen, treated, Trial, Women
Posted in Treatment | No Comments »
Conclusion
Combination chemotherapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse effects in patients with advanced biliary cancers. On the basis of preliminary molecular analysis, presence of a k-ras mutation may alter erlotinib efficacy. The combination of bevacizumab and erlotinib may be a therapeutic alternative in patients with advanced biliary cancer. (Source: Journal of Clinical Oncology)
Source: MedWorm: Oral Cancer
Tags: Bevacizumab, Biliary, Biweekly, Cancer, Combination, consortium, Daily, Erlotinib, Gastrointestinal, Multicenter, patients, Phase, Report, Study, Testing, Trial, Unresectable
Posted in Treatment | No Comments »
Preventive treatment for those at risk for bone loss may minimize adverse effects of anastrozole. Breast Cancer Research (Source: Medscape Today Headlines)
Source: MedWorm: Oral Cancer
Tags: AnastrozoleInduced, ARBI, Bone, Breast, Cancer, Clinical, Loss, Management, Oral, patients, Prospective, Results, Risedronate, Trial
Posted in Treatment | No Comments »
Conclusion: Single-agent oral vinorelbine is extremely safe in elderly patients with advanced NSCLC and ECOG PS of two or more and may represent a valid option in this very special population. (Source: Annals of Oncology)
Source: MedWorm: Oral Cancer
Tags: >=70, Advanced, Cancer, Elderly, lung, nonsmallcell, Oral, patients, performance, Phase, Poor, singleagent, Status, Trial, vinorelbine, years
Posted in Treatment | No Comments »
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced that data from the Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial evaluating the efficacy and safety of picoplatin as a second-line treatment in small cell lung cancer (SCLC) has been accepted for an oral presentation during the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting… (Source: Health News from Medical News Today)
Source: MedWorm: Oral Cancer
Tags: Announces, Cancer, cell, lung, Pharmaceuticals, Phase, Picoplatin, Poniard, Results, Small, SPEAR, Trial
Posted in Treatment | No Comments »
Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer (NSCLC). Following treatment with erlotinib, patients in the group classified as “VeriStrat Good” had a median survival of 10.5 months compared to 4.0 months in the group classified as “VeriStrat Poor… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: Cancer, Data, Erlotinib, Identifies, likely, lung, patients, Phase, Respond, Trial, VeriStratR
Posted in Treatment | No Comments »
ZIOPHARM Oncology, Inc., announced it has initiated a Phase I/II study at Memorial Sloan- Kettering Cancer Center for the novel, mathematically – determined administration of oral indibulin in the treatment of metastatic breast cancer. (Source: Cancercompass News: Breast Cancer)
Source: MedWorm: Oral Cancer
Tags: Breast, Cancer, Commences, I/II, Indibulin, Oral, Phase, Trial, ZIOPHARM
Posted in Treatment | No Comments »
Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. announced publication of positive results from their previously reported Phase 1-2 trial of the novel triple-acting oral androgen receptor antagonist MDV3100 in men with progressive, metastatic castration-resistant prostate cancer in the April 15 online version of The Lancet. According to the published results, MDV3100 demonstrated anti-tumor activity in patients with late-stage prostate cancer as evaluated by reductions in prostate specific antigen (PSA) levels, radiographic findings and circulating tumor cell (CTC) counts… (Source: Health News from Medical News Today)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.
Source: MedWorm: Oral Cancer
Tags: Announce, Astellas, Cancer, Data, efficacy, Lancet, MDV3100, Medivation, Patiens, Phase, Positive, Prostate, Publication, Trial
Posted in Treatment | No Comments »
